$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
Masking Technology Could Address Safety Limitations Of Solid Tumor Candidates
Executive Summary
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.
You may also be interested in...
Biogen Marginally Outbid Another Big Pharma For $7.3bn Reata Acquisition
The US firm’s multi-billion dollar buyout of the rare disease biotech Reata was not so straightforward according to a recent security filing that detailed a back-and-forth bidding process between Biogen and a rival company that initiated first contact, believed to be Sanofi.
Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.